COMPARISON

GHK-Cu vs Plecanatide

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

GHK-Cu is authorised or registered in 0 and Plecanatide in 2 of the 10 registers read. GHK-Cu: highest phase Phase 4 (after approval). Plecanatide: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

GHK-CuPlecanatide
Registered trials
differs
3
clinicaltrials.gov · 2026-10-03
15
clinicaltrials.gov · 2026-10-03
FDA label
differs
Not checked
no record of "fdaLabel" for ghk-cu
FDA-approved: Trulance Immediate release
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectGHK-CuplaceboPlecanatideplacebo
Diarrhoea--5.8%1.2%
Headache--2.3%1.6%

Trial register GHK-Cu: 0 placebo-controlled trials; Plecanatide: 8. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. GHK-Cu side effects · Plecanatide side effects

LEGAL STATUS

Approval in each country read

CountryGHK-CuPlecanatideRegister
United StatesNot on the registerFDA-approvedRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomNot on the registerNot on the registerRegulator MHRA
CanadaNot on the registerAuthorisedRegulator Health Canada
AustraliaStatus unknownStatus unknown TGA
SwitzerlandNot on the registerNot on the registerRegulator Swissmedic
BrazilNot on the registerNot on the registerRegulator ANVISA
SerbiaNot on the registerNot on the registerRegulator ALIMS
SingaporeNot on the registerNot on the registerRegulator HSA
TurkeyNot on the registerNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.